AI Summary
✦ ClarthaValuation Metrics
Trading 26.4% above historical median. Valuation is declining — currently in the fair zone (z-score: +0.22). Confidence: 63%.
Live forward EPS implies next-12-month EPS of ₹43.30. Applying the stock's normalized valuation corridor produces a fair range of ₹7,638.55 to ₹11,708.75, with base value near ₹8,557.38 (+693.0% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹43.30
Forward P/E
24.9x
Base Fair Value
₹8,557.38
Fair Range
₹7,638.55 - ₹11,708.75
Upside To Base
+693.0%
Estimate Source
Live forward EPS
5Y Average
178.72
Current
249.84
Overvalued
270.41
Undervalued
176.41
5Y Average
6.00
Current
9.04
Overvalued
8.08
Undervalued
3.30
5Y Average
3.01
Current
4.25
Overvalued
3.47
Undervalued
2.56
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Undervalued | -34% vs avg | -25.8% |
ASTRAZENECA PHARMA IND LT ASTRAZENPharmaceuticals | +20.4% | 8.2% | 107.4x Premium | +62% vs avg | -6.9% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 162.0x Premium | +144% vs avg | -52.7% |
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -53% vs avg | +22.1% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.0x Undervalued | -58% vs avg | +43.4% |
CONCORD BIOTECH LIMITED CONCORDBIOPharmaceuticals | +26.2% | 24.8% | 48.8x Undervalued | -27% vs avg | -14.9% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.8x Undervalued | -34% vs avg | +45.4% |
ORCHID PHARMA LIMITED trades at a premium (269.1x vs peer avg 66.4x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include BLUE JET HEALTHCARE LTD, ASTRAZENECA PHARMA IND LT, COHANCE LIFESCIENCES LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹238 CrMar 2026Latest net profit
₹31 CrMar 2026Latest EPS
₹6.03Mar 2026Net margin
12.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 210 | 183 | 199 | 221 | 217 | 244 | 223 | 217 | 237 | 173 | 194 | 207 | 238 |
| Expenses + | 170 | 161 | 175 | 185 | 188 | 211 | 193 | 191 | 203 | 159 | 194 | 204 | 209 |
| Operating Profit | 40 | 22 | 24 | 36 | 29 | 33 | 30 | 26 | 34 | 14 | -1 | 3 | 29 |
| OPM % | 19% | 12% | 12% | 16% | 13% | 14% | 13% | 12% | 14% | 8% | -0.3% | 1.4% | 12% |
| Other Income + | 40 | 2 | 8 | 7 | 13 | 8 | 8 | 10 | 6 | 16 | 15 | 3 | 14 |
| Interest | 7 | 6 | 4 | 4 | 3 | 3 | 3 | 4 | 4 | 3 | 4 | 3 | 3 |
| Depreciation | 7 | 8 | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Profit before tax | 65 | 11 | 20 | 31 | 30 | 29 | 26 | 24 | 28 | 18 | 2 | -6 | 31 |
| Tax % | 0% | 0% | 0% | 0% | -11% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit + | 65 | 11 | 20 | 31 | 33 | 29 | 26 | 24 | 28 | 18 | 2 | -6 | 31 |
| EPS in Rs | 15.89 | 2.13 | 3.99 | 6.02 | 6.54 | 5.74 | 5.05 | 4.71 | 5.49 | 3.59 | 0.44 | -1.15 | 6.03 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Board Meeting Outcome for Outcome Of Board Meeting Held On August 01, 2026
Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On August 01, 2026